JP2010513539A5 - - Google Patents

Download PDF

Info

Publication number
JP2010513539A5
JP2010513539A5 JP2009542980A JP2009542980A JP2010513539A5 JP 2010513539 A5 JP2010513539 A5 JP 2010513539A5 JP 2009542980 A JP2009542980 A JP 2009542980A JP 2009542980 A JP2009542980 A JP 2009542980A JP 2010513539 A5 JP2010513539 A5 JP 2010513539A5
Authority
JP
Japan
Prior art keywords
seq
heavy chain
light chain
amino acid
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009542980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513539A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/078568 external-priority patent/WO2008079466A1/en
Publication of JP2010513539A publication Critical patent/JP2010513539A/ja
Publication of JP2010513539A5 publication Critical patent/JP2010513539A5/ja
Pending legal-status Critical Current

Links

JP2009542980A 2006-12-20 2007-09-14 抗体とその製造法および使用法 Pending JP2010513539A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87106906P 2006-12-20 2006-12-20
PCT/US2007/078568 WO2008079466A1 (en) 2006-12-20 2007-09-14 Antibodies and methods for making and using them

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013169145A Division JP2014028812A (ja) 2006-12-20 2013-08-16 抗体とその製造法および使用法

Publications (2)

Publication Number Publication Date
JP2010513539A JP2010513539A (ja) 2010-04-30
JP2010513539A5 true JP2010513539A5 (enExample) 2010-09-30

Family

ID=39536929

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009542980A Pending JP2010513539A (ja) 2006-12-20 2007-09-14 抗体とその製造法および使用法
JP2013169145A Pending JP2014028812A (ja) 2006-12-20 2013-08-16 抗体とその製造法および使用法
JP2015056137A Pending JP2015145394A (ja) 2006-12-20 2015-03-19 抗体とその製造法および使用法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013169145A Pending JP2014028812A (ja) 2006-12-20 2013-08-16 抗体とその製造法および使用法
JP2015056137A Pending JP2015145394A (ja) 2006-12-20 2015-03-19 抗体とその製造法および使用法

Country Status (10)

Country Link
US (3) US8465741B2 (enExample)
EP (3) EP2121756A4 (enExample)
JP (3) JP2010513539A (enExample)
KR (2) KR101546441B1 (enExample)
CN (2) CN101675074B (enExample)
AU (1) AU2007338607B2 (enExample)
BR (1) BRPI0720565A2 (enExample)
CA (2) CA2673725C (enExample)
MX (1) MX2009006659A (enExample)
WO (2) WO2008076487A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465741B2 (en) * 2006-12-20 2013-06-18 Mmrglobal, Inc. Antibodies and methods for making and using them
CA2744103C (en) * 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
CN105777907B (zh) 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
CA2800311A1 (en) 2010-05-11 2011-11-17 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
WO2012092374A2 (en) 2010-12-31 2012-07-05 Short Jay M Express humanization of antibodies
AU2011352207B2 (en) * 2010-12-31 2016-03-03 Bioatla, Llc Comprehensive monoclonal antibody generation
US20140050733A1 (en) * 2011-02-07 2014-02-20 Dale B. Schenk Apoe immunotherapy
ES2661466T3 (es) 2011-04-01 2018-04-02 Immunogen, Inc. Métodos para aumentar la eficacia de la terapia contra el cáncer con FOLR1
US9790280B2 (en) 2011-10-26 2017-10-17 Elanco Tiergesundheit Ag Monoclonal canine CD20 antibodies and methods of use
US12384848B2 (en) 2011-12-19 2025-08-12 The Rockefeller University Anti-inflammatory polypeptides
EA201892339A3 (ru) * 2011-12-19 2019-06-28 Дзе Рокфеллер Юниверсити Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
SG11201500938XA (en) 2012-08-31 2015-04-29 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
JP2016501877A (ja) 2012-11-28 2016-01-21 シーエヌジェー ホールディングス,インコーポレイテッド クロストリジウム・ディフィシルに対する抗体
NZ717140A (en) 2013-08-30 2022-05-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
EA202191471A1 (ru) 2015-03-04 2022-01-31 Зе Рокфеллер Юниверсити Противовоспалительные полипептиды
CN122075735A (zh) 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
JP7120989B2 (ja) 2016-07-06 2022-08-17 セルジーン コーポレイション 低免疫原性を有する抗体及びその使用
MY205541A (en) * 2017-08-03 2024-10-25 Alector Llc Anti-cd33 antibodies and methods of use thereof
AU2019330494A1 (en) * 2018-08-31 2021-03-25 Immune Biosolutions Inc Antibodies specific for NTSR1 and uses thereof
CN111662382A (zh) * 2019-03-06 2020-09-15 瑞阳(苏州)生物科技有限公司 特异结合cd3的抗体、抗原结合片段和单链抗体可变区片段及其应用
JP7370569B2 (ja) * 2019-08-07 2023-10-30 国立大学法人 大分大学 アミロイドβタンパク質オリゴマーと結合するヒト化抗体
CN115803340A (zh) * 2020-04-24 2023-03-14 纪念斯隆凯特琳癌症中心 抗cd3抗体及其用途
CN116635948A (zh) * 2020-12-07 2023-08-22 Absci公司 用于产生疾病相关蛋白质组合物的系统和方法
WO2025024323A1 (en) * 2023-07-21 2025-01-30 Bighat Biosciences, Inc. P- and e-selectin-binding compositions and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
PT528767E (pt) * 1991-08-21 2000-06-30 Novartis Ag Derivados de anticorpos
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
JP2000169393A (ja) * 1998-09-30 2000-06-20 Sankyo Co Ltd 抗Fas抗体を含有する医薬
TWI314933B (en) 2000-05-26 2009-09-21 Bristol Myers Squibb Compan Soluble ctla4 mutant molecules and uses thereof
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
CA2476166C (en) * 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
AU2004242845B2 (en) 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
US20060228350A1 (en) 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US8076459B2 (en) * 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
HUE038955T2 (hu) * 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
RU2006140377A (ru) * 2004-04-16 2008-05-27 Дженентек, Инк. (Us) Способ усиления уничтожения в-клеток
RU2006142857A (ru) 2004-05-05 2008-06-10 Дженентек, Инк. (Us) Профилактика аутоиммунного заболевания
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1869192B1 (en) * 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
EP1891113A2 (en) 2005-06-02 2008-02-27 AstraZeneca AB Antibodies directed to cd20 and uses thereof
MY149159A (en) * 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
KR101866623B1 (ko) * 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
US8465741B2 (en) 2006-12-20 2013-06-18 Mmrglobal, Inc. Antibodies and methods for making and using them

Similar Documents

Publication Publication Date Title
JP2021191763A5 (enExample)
JP2022512132A5 (enExample)
JP2020180158A5 (enExample)
JP2009225799A5 (enExample)
JP2008542278A5 (enExample)
JP2022037133A (ja) 改良された血清アルブミン結合剤
JP2017501711A5 (enExample)
JP2024532485A5 (enExample)
JP2020525032A5 (enExample)
JP2021503455A5 (enExample)
JP2010536384A5 (enExample)
JP2010534478A5 (enExample)
JP2018526981A5 (enExample)
JP2011207882A5 (enExample)
JP2013517330A5 (enExample)
JP2014511179A5 (enExample)
JP2017533694A5 (enExample)
JP2017507652A5 (enExample)
JP2012504955A5 (enExample)
JP2013506428A5 (enExample)
JP2011517447A5 (enExample)
JP2016516400A5 (enExample)
JP2024541680A5 (enExample)
JP2022549172A5 (enExample)
JP2023509390A5 (enExample)